M. E. Lebsack

619 total citations
10 papers, 461 citations indexed

About

M. E. Lebsack is a scholar working on Pharmacology, Pharmacology and Molecular Medicine. According to data from OpenAlex, M. E. Lebsack has authored 10 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 2 papers in Pharmacology and 2 papers in Molecular Medicine. Recurrent topics in M. E. Lebsack's work include Antibiotics Pharmacokinetics and Efficacy (4 papers), Poisoning and overdose treatments (2 papers) and Antibiotic Resistance in Bacteria (2 papers). M. E. Lebsack is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (4 papers), Poisoning and overdose treatments (2 papers) and Antibiotic Resistance in Bacteria (2 papers). M. E. Lebsack collaborates with scholars based in United States and Canada. M. E. Lebsack's co-authors include Gary V. Gordon, Janice L. Lookabaugh, G. Campion, Abbe Rubin, Joan Korth‐Bradley, Roberta Hanna, Donna Simcoe, Allen J. Sedman, Jerome J. Schentag and John H. Wilton and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

M. E. Lebsack

10 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. E. Lebsack United States	6	188	111	105	93	85	10	461
T J Constable United Kingdom	9	273 1.5×	57 0.5×	101 1.0×	43 0.5×	57 0.7×	12	551
J. Gooi United Kingdom	6	217 1.2×	85 0.8×	110 1.0×	111 1.2×	43 0.5×	9	504
José Luis Marenco Spain	14	339 1.8×	131 1.2×	39 0.4×	149 1.6×	67 0.8×	43	657
David L. Hyslop United States	7	196 1.0×	54 0.5×	89 0.8×	16 0.2×	36 0.4×	14	394
Sung‐Hwan Park South Korea	9	138 0.7×	99 0.9×	27 0.3×	19 0.2×	84 1.0×	11	384
Shin Okuyama Japan	13	110 0.6×	82 0.7×	43 0.4×	12 0.1×	119 1.4×	38	527
Dong-Hui Zheng China	14	276 1.5×	81 0.7×	56 0.5×	16 0.2×	124 1.5×	28	554
Marina Mantzourani Greece	13	29 0.2×	58 0.5×	125 1.2×	23 0.2×	151 1.8×	48	463
Yaowei Zhu United States	14	208 1.1×	843 7.6×	221 2.1×	16 0.2×	97 1.1×	19	1.1k
Faruk Özer Türkiye	12	51 0.3×	35 0.3×	92 0.9×	55 0.6×	106 1.2×	26	440

Countries citing papers authored by M. E. Lebsack

Since Specialization

Citations

This map shows the geographic impact of M. E. Lebsack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Lebsack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Lebsack more than expected).

Fields of papers citing papers by M. E. Lebsack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Lebsack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Lebsack. The network helps show where M. E. Lebsack may publish in the future.

Co-authorship network of co-authors of M. E. Lebsack

This figure shows the co-authorship network connecting the top 25 collaborators of M. E. Lebsack. A scholar is included among the top collaborators of M. E. Lebsack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. E. Lebsack. M. E. Lebsack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Korth‐Bradley, Joan, Abbe Rubin, Roberta Hanna, Donna Simcoe, & M. E. Lebsack. (2000). The Pharmacokinetics of Etanercept in Healthy Volunteers. Annals of Pharmacotherapy. 34(2). 161–164. 117 indexed citations

2.

Lebsack, M. E., et al.. (1997). Safety of FLT3 ligand in healthy volunteers. 1. 170. 15 indexed citations

3.

Campion, G., M. E. Lebsack, Janice L. Lookabaugh, & Gary V. Gordon. (1996). Dose‐range and dose‐frequency study of recombinant human interleukin‐1 receptor antagonist in patients with rheumatoid arthritis. Arthritis & Rheumatism. 39(7). 1092–1101. 196 indexed citations

4.

Vose, J. M., J Anderson, P. J. Bierman, et al.. (1996). Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy.. Journal of Clinical Oncology. 14(2). 520–526. 9 indexed citations

5.

Nix, David E., et al.. (1993). Effect of oral antacids on disposition of intravenous enoxacin. Antimicrobial Agents and Chemotherapy. 37(4). 775–777. 5 indexed citations

6.

Stringer, Kathleen A., et al.. (1992). Effect of Cimetidine Administration on the Pharmacokinetics of Pirmenol. The Journal of Clinical Pharmacology. 32(1). 91–94. 2 indexed citations

7.

Lebsack, M. E., David E. Nix, Roger D. Toothaker, et al.. (1992). Effect of gastric acidity on enoxacin absorption. Clinical Pharmacology & Therapeutics. 52(3). 252–256. 25 indexed citations

8.

Stringer, Kathleen A., et al.. (1991). The Effect of Pirmenol Administration on the Anti‐coagulant Activity of Warfarin. The Journal of Clinical Pharmacology. 31(7). 607–610. 2 indexed citations

9.

Grasela, Thaddeus H., Jerome J. Schentag, Allen J. Sedman, et al.. (1989). Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrobial Agents and Chemotherapy. 33(5). 615–617. 85 indexed citations

10.

Stringer, Kathleen A., et al.. (1988). Enhanced Pirmenol Elimination by Rifampin. The Journal of Clinical Pharmacology. 28(12). 1094–1097. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact